Topoisomerase II Alpha Gene Amplification and Protein Overexpression Predicting Efficacy of Epirubicin (TOP)
Prospective Evaluation of Topoisomerase II Alpha Gene Amplification and Protein Overexpression as Markers Predicting the Efficacy of Epirubicin in the Primary Treatment of Breast Cancer Patients
Sponsor: Centre Hospitalier du Luxembourg
Terminated
Low accrual rate
Listed as NCT00162812, this PHASE2 trial focuses on Breast Cancer and remains terminated or withdrawn. Sponsored by Centre Hospitalier du Luxembourg, it has been updated 7 times since 2003, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Jan 2026 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jun 2020 — Jan 2021 [monthly]
Terminated PHASE2
▶ Show 2 earlier versions
-
Jun 2018 — Jun 2020 [monthly]
Terminated PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE2
First recorded
Jan 2003
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Centre Hospitalier du Luxembourg
- Centre Paul Strauss
- Clinique Louis Cathy - Baudour - Belgium
- Clinique Saint Pierre Ottignies
- Clinique Ste Elisabeth - Namur - Belgium
- Feculdade de Medicina da Universidade de Sao Paulo - Brasil
- Gustave Roussy, Cancer Campus, Grand Paris
- HIS - Site Etterbeek - Ixelles - Belgium
- Jules Bordet Institute
- University Hospital of Crete
For direct contact, visit the study record on ClinicalTrials.gov .